FDA

#AstraZeneca #BioIndustry Association #Biotech #Boehringer Ingelheim #FDA #Gene therapy #Genetics #Hearing Loss #HIV #Investment #Malaria #Novartis #UK #WHO

DDW Highlights: 6 May 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, the UK made headlines for both the investment it has attracted and… Read More

#Podcasts

Patient holding pill in hand
#ALS #Fast Track designation #FDA #Spinogenix

FDA grants Fast Track Designation to ALS pill 

The US Food and Drug Administration (FDA) has granted Fast Track Designation to a treatment for amyotrophic lateral sclerosis (ALS).  Tazbentetol, developed by biopharmaceutical company Spinogenix, is a once-a-day pill with potential to restore synapses, the key connections between neurons that allow people to think, plan, remember and control movement. … Read More

#News #Regulatory

FDA headquarters
#Clinical trial design #Clinical trials #FDA #Real-time clinical trials

FDA moves towards real-time clinical trials

The US Food and Drug Administration has announced two major steps as part of an initiative to advance the implementation of real-time clinical trials (RTCT).   First, the agency unveiled the successful initiation of two proof-of-concept clinical trials that will report endpoints and data signals to the agency in real time. Read More

#Editor's Choice #News #Regulatory #Trending News

#AstraZeneca #BioIndustry Association #Biotech #Boehringer Ingelheim #FDA #Gene therapy #Genetics #Hearing Loss #HIV #Investment #Malaria #Novartis #UK #WHO

This week in Drug Discovery (27 April – 1 May) 

News round-up for 27 April – 1 May by Bruno Quinney, Content Team at DDW.  This week, the UK has made headlines for both the investment it has attracted and the clinical trial reforms it has rolled out. Elsewhere, the world’s first antimalarial drug for newborns could soon address a critical unmet… Read More

#News

Woman using an asthma inhaler
#Asthma #AstraZeneca #FDA

FDA approves first asthma triple therapy in US

The US Food and Drug Administration (FDA) has approved the first and only triple therapy for patients 12 years and older with asthma.  AstraZeneca’s fixed-dose triple-combination therapy Breztri Aerosphere has been approved in the US for the maintenance treatment of asthma in adult and paediatric patients 12 years of age and older.   Breztri is… Read More

#News #Regulatory

FDA headquarters
#Clinical trial #FDA #Newron Pharmaceuticals #Schizophrenia

FDA pauses schizophrenia trial after patient death 

The US Food and Drug Administration (FDA) has paused a trial evaluating a drug for treatment-resistant schizophrenia (TRS) after the death of a participant.  Evenamide, developed by biopharmaceutical company Newron Pharmaceuticals, was being evaluated in the Phase III ENIGMA-TRS 2 study, targeting the modulation of excessive release of glutamate in patients suffering from… Read More

#News #Regulatory

Gene therapy
#FDA #Gene therapy #Hearing Loss #Regeneron Pharmaceuticals

FDA approves first gene therapy for genetic hearing loss

The US Food and Drug Administration (FDA) has granted accelerated approval for Regeneron Pharmaceuticals’ Otarmeni (lunsotogene parvec-cwha), the first gene therapy and second new molecular entity approved under the FDA Commissioner’s National Priority Voucher programme.   Otarmeni is an adeno-associated virus vector-based gene therapy indicated for the treatment of paediatric and… Read More

#News #Regulatory #Trending News

#AC Immune #Alzheimer's #Cancer Grand Challenges #Cancer immunotherapy #Childhood cancer #Clinical trial #Eli Lilly #FDA #Francis Crick Institute #Genetics #GLP-1 #Neurodevelopmental disorders

DDW Highlights: 14 April 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, researchers discovered how genetic mutations cause a previously unknown recessive condition. Elsewhere, Eli… Read More

#Podcasts

#AC Immune #Alzheimer's #Cancer Grand Challenges #Cancer immunotherapy #Childhood cancer #Clinical trial #Eli Lilly #FDA #Francis Crick Institute #Genetics #GLP-1 #Neurodevelopmental disorders

This week in Drug Discovery (6 – 10 April) 

News round-up for 6 – 10 April by Bruno Quinney, Content Team at DDW.  This week, researchers have discovered how genetic mutations cause a previously unknown recessive condition. Elsewhere, Lilly has made the headlines for both an approved drug and a drug collaboration.  The top stories: … Read More

#News

Pills
#Eli Lilly #FDA #GLP-1 #Obesity #Weight loss

FDA approves Lilly’s GLP-1 pill for weight loss

The US Food and Drug Administration (FDA) has approved Foundayo (orforglipron) for adults with obesity, or overweight with weight-related medical problems.   "People living with obesity need treatment options that meet them where they are – and for many, a once-daily pill that can be taken with no food or water… Read More

#News #Regulatory #Trending News

#AI / data analytics / healthtech / informatics #ALS #Alzheimer's #Axol Bioscience #Biologics #Centessa Pharmaceuticals #Corcept Therapeutics #Denali Therapeutics #Eli Lilly #FDA #Hunter Syndrome #LifeArc #Mergers and acquisitions #MND #Ovarian cancer #Stanford University

DDW Highlights: 7 April 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, there were crucial developments in neuroscience drug discovery. Elsewhere, a new treatment for… Read More

#Podcasts

Ovarian cancer
#Corcept Therapeutics #FDA #Oncology #Ovarian cancer

Platinum-resistant ovarian cancer drug gets FDA green light

The US Food and Drug Administration (FDA) has approved Lifyorli (relacorilant) in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.  It is approved in patients who have received one to three prior systemic treatment regimens, at least one of which… Read More

#News #Regulatory

Cell and gene therapy
#FDA #Gene therapy #Paediatrics #Rare disease #Rocket Pharmaceuticals

First gene therapy for rare paediatric disease gets US approval

The US Food and Drug Administration (FDA) has granted accelerated approval for Kresladi (marnetegragene autotemcel), an autologous haematopoietic stem cell-based gene therapy.  It is indicated for the treatment of paediatric patients with severe leukocyte adhesion deficiency-I (LAD-I) due to biallelic variants in ITGB2 without an available human leukocyte antigen-matched sibling… Read More

#News #Regulatory #Trending News

Human brain
#Biologics #Denali Therapeutics #FDA #Hunter Syndrome

FDA approves Denali’s Hunter syndrome treatment

The US Food and Drug Administration (FDA) has granted accelerated approval for Avlayah (tividenofusp alfa-eknm), the first FDA-approved biologic specifically designed to cross the blood-brain barrier.   Avlayah is an enzyme replacement therapy indicated for the treatment of neurologic manifestations of Hunter syndrome (mucopolysaccharidosis type II, or MPS II) when initiated… Read More

#News #Regulatory

Patient with dry eye disease using eye drops
#Aldeyra Therapeutics #Dry eye #FDA #Ophthalmology

FDA finds lack of evidence for dry eye disease drug approval

Aldeyra Therapeutics has received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) for the New Drug Application (NDA) of reproxalap, an investigational drug candidate, for the treatment of dry eye disease.   The CRL states that there is “a lack of substantial evidence consisting of adequate… Read More

#News #Regulatory